Aktuellt
SENASTE
Redeye provides an update in relation to Optomed’s Q2 2023 report. The report aligned with our expectations and did not include any major surprises. However, we note that the additional data has not been sent in yet to the FDA. We now expect a potential FDA approval during Q4 2023 and only make some minor estimate changes for Q3-Q4 2023e. Moreover, we believe an exciting half-year is ahead of Optomed and argue the share is currently traded at low levels, significantly lower than our reiterated base case of EUR8.
LÄS MER
